SynRx Therapeutics
Latest round
- Series A
Last raised
- Dec 2025
Total raised
- Undisclosed
Investors
- 6
About SynRx Therapeutics
, trading as SynRx Therapeutics, develops innovative oncology therapeutics focused on DNA damage repair pathways. The company was founded by Professor Yu Xiaochun, a faculty member of Westlake University and the University of Michigan, who has published over 100 academic papers and patents. SynRx has expanded operations with an additional site in Shanghai and has advanced multiple first-in-class small molecule drug candidates into preclinical and early clinical development. The company develops small molecule drug candidates targeting DNA damage repair mechanisms for oncology indications. Its pipeline includes preclinical and clinical stage programs designed for homologous recombination repair deficient solid tumors and other malignancies. Drug candidates under development include SY001, SY002, SY003, SY004 and SY005, which are evaluated for application in late stage clinical cancer treatment. The company’s revenue model includes research collaborations, licensing agreements with development and commercialization of its drug candidates.
Who invested in SynRx Therapeutics
6 investors across 2 rounds
See all investors in SynRx Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about SynRx Therapeutics
Who invested in SynRx Therapeutics?
SynRx Therapeutics has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has SynRx Therapeutics raised?
SynRx Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did SynRx Therapeutics last raise money?
SynRx Therapeutics's most recent round on record is a Series A, in Dec 2025.
What does SynRx Therapeutics do?
, trading as SynRx Therapeutics, develops innovative oncology therapeutics focused on DNA damage repair pathways.
Where is SynRx Therapeutics headquartered?
SynRx Therapeutics is headquartered in Hangzhou, China.
Which VCs invest in companies like SynRx Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at SynRx Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like SynRx Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.